CEL-SCI Co. (CVM) Sees Large Growth in Short Interest
CEL-SCI Co. (NYSEAMERICAN:CVM) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 2,543,528 shares, an increase of 1.6% from the December 14th total of 2,504,696 shares. Currently, 9.5% of the shares of the company are sold short. Based on an average daily volume of 186,318 shares, the short-interest ratio is presently 13.7 days.
Shares of CVM stock opened at $2.76 on Friday. CEL-SCI has a 12-month low of $0.82 and a 12-month high of $4.44.
Hedge funds have recently modified their holdings of the company. D.A. Davidson & CO. purchased a new stake in shares of CEL-SCI during the 3rd quarter worth approximately $567,000. Vanguard Group Inc increased its stake in shares of CEL-SCI by 29.7% during the 3rd quarter. Vanguard Group Inc now owns 562,208 shares of the company’s stock worth $2,277,000 after purchasing an additional 128,764 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of CEL-SCI by 29.7% during the 3rd quarter. Vanguard Group Inc. now owns 562,208 shares of the company’s stock worth $2,277,000 after purchasing an additional 128,764 shares during the last quarter. Finally, BlackRock Inc. increased its stake in shares of CEL-SCI by 370.7% during the 3rd quarter. BlackRock Inc. now owns 603,914 shares of the company’s stock worth $2,446,000 after purchasing an additional 475,600 shares during the last quarter.
COPYRIGHT VIOLATION NOTICE: This article was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2019/01/12/cel-sci-co-cvm-sees-large-growth-in-short-interest.html.
CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company's Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts.
Further Reading: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.